Jupiter Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Jupiter Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-218,895	Closed	-$19.7M	–	503
2020 Q1	$19.7M	Sell	218,895 -58,353	-21%	-$5.73M	0.38%	79
2019 Q4	$30M	Buy	277,248 +162,232	+141%	+$17.4M	0.42%	72
2019 Q3	$11.3M	Buy	+115,016	New	+$13M	0.15%	160
2015 Q3	–	Sell	-76,015	Closed	-$13.7M	–	420
2015 Q2	$13.7M	Sell	76,015 -198,405	-72%	-$34.2M	0.4%	76
2015 Q1	$47.6M	Buy	274,420 +109,727	+67%	+$19.9M	1.51%	21
2014 Q4	$30.5M	Buy	+164,693	New	+$30.5M	1.08%	27

Other funds holding ALXN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jupiter Investment Management's ALXN Position: Q2 2020 in Review

Jupiter Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 218,895 shares — an estimated $19.7M sold.

Jupiter Investment Management first reported a position in ALXN in Q4 2014 and held it in 6 quarters. The position peaked at $47.6M in Q1 2015. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Jupiter Investment Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Jupiter Investment Management sold 218,895 Alexion Pharmaceuticals shares in Q2 2020, an estimated $19.7M.
Jupiter Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Jupiter Investment Management's Alexion Pharmaceuticals position peaked at $47.6M in Q1 2015.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Jupiter Investment Management's 13F filing for Q2 2020, filed 13 Jul 2020.